The primary objective of this trial is to determine the effect on pain intensity scored of ZD6416 1600 mg administered twice daily for 2 weeks in adult subjects with painful distal symmetrical sensory polyneuropathy (DSSP) compared with placebo. Of the 5 known prostanoid mediators that are synthesized in man, prostaglandin E2 (PGE2) appears to play an important role in the modulation of pain in the periphery (Egg 1984) and in the spinal cord (Coderre et al 1990). There is evidence that PGE2 can interact with at least 4 distinct receptors EP1, EP2, EP3 and EP4 (Coleman et al 1994). The modulation of pain responses by PGE2 appears to be due to its actions at the EP1 receptor because of putative EP1 receptor antagonist AH6809 was shown to antagonize the hyperalgesic effects of intrathecally applied PGE2 in animals (Uda et al 1990). In animal models of pain (Bennett 1994), which are thought to involve central sensitization (second phase formalin model and chronic constriction injury model), EP1 antagonists developed by Zeneca Pharmaceuticals, Zeneca Inc. (Zeneca), and including ZD6416, have been shown to be analgesic. This trial, which is designed to assess whether ZD6416 is analgesic in subjects with neuropathic pain secondry to diabetic distal symmetrical sensory polyneuropathy (DSSP), as the pain in this condition is thought to involve pain mechanisms including central sensitization.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
General Clinical Research Centers Program (M01)
Project #
5M01RR001066-23
Application #
6409764
Study Section
National Center for Research Resources Initial Review Group (RIRG)
Project Start
1978-02-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
23
Fiscal Year
2000
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Fourman, Lindsay T; Czerwonka, Natalia; Shaikh, Sofia D et al. (2018) Insulin-like growth factor 1 inversely relates to monocyte/macrophage activation markers in HIV. AIDS 32:927-932
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Arslanian, Silva; El Ghormli, Laure; Kim, Joon Young et al. (2018) The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test: Forerunner of Heightened Glycemic Failure Rates and Accelerated Decline in ?-Cell Function in TODAY. Diabetes Care :
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Foldyna, Borek; Fourman, Lindsay T; Lu, Michael T et al. (2018) Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr 78:421-428
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Srinivasa, Suman; Lu, Michael T; Fitch, Kathleen V et al. (2018) Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther 23:1-9

Showing the most recent 10 out of 945 publications